August 27, 2017Open Access
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
Structured PICO
Does rivaroxaban with or without aspirin improve cardiovascular outcomes in patients with stable atherosclerotic vascular disease?
P
Population
Patients with stable atherosclerotic vascular disease
I
Intervention
Rivaroxaban (2.5 mg twice daily) plus aspirin, or rivaroxaban (5 mg twice daily) alone
C
Comparator
Aspirin alone
O
Outcome
Cardiovascular outcomescomposite
In patients with stable atherosclerotic vascular disease, adding rivaroxaban 2.5 mg twice daily to aspirin improves cardiovascular outcomes but increases major bleeding, while rivaroxaban 5 mg twice daily alone offers no cardiovascular benefit over aspirin alone.
Abstract
Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events. (Funded by Bayer; COMPASS ClinicalTrials.gov number, NCT01776424 .).
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
John W. Eikelboom
Université Claude Bernard Lyon 1
S
Stuart J. Connolly
Electrophysiology
J
Jackie Bosch
Preventive Cardiology
Journals
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)
New England Journal of Medicine
Actions
Institutions
Harvard University
University of Washington
University College London
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...